01.02.2024 • NewsArkemaelastomers

Arkema Increases Global Pebax Elastomers Production Capactiy 40%

Arkema has increased its global manufacturing capacity for Pebax elastomers by 40% at its Serquigny plant in France, which is utilized in particular in the sports and consumer goods markets.

Arkema has started its new Pebax elastomer unit at the Serquigny plant in France. This new unit, designed with the latest advancements in industrial processes, can produce both the bio-circular Pebax Rnew and classical Pebax elastomer ranges.

These advanced materials are used extensively in sports equipment such as running shoes, soccer shoes and ski boots, but also in electronic devices, and other specialty markets such as antistatic additives and medical devices.

"We are excited to start the production of this expansion in our Pebax elastomers capacity. This represents a great opportunity for us to meet growing demand in existing and new applications while simultaneously improving our processes as water consumption at the site will be reduced by approximately 25%,” commented Erwoan Pezron, Senior Vice-President of Arkema's High-Performance Polymers Business Line.

Company

Logo:

Arkema

420 rue d’Estienne d’Orves
92705 Colombes Cedex
France

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.